Little is understood about which pts are at risk for therapy-associated acute myeloid leukemia. The reporter gene hprt has established sensitivity & specificity as a biomarker in lymphocytes for detecting in vivo somatic mutation due to chemotherapy. We recently developed methods to measure in vivo hprt somatic mutation in myeloid stem cells & to analyze the molecular nature of the mutations. We hypothesize that hprt in myeloid cells will reflect the specific mutational pressure of cytotoxic therapies that lead to tAML.
Showing the most recent 10 out of 94 publications